Anders Martin-Löf

Director of Finance/CFO at BIOARCTIC AB

Net worth: 15 197 $ as of 2024-04-29

53 year

68 connections

Health Technology

Consumer Services

Technology Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Lars Gunnar Lannfelt	M	75	BIOARCTIC AB	21 years
Pär Lars Gellerfors	M	77	BIOARCTIC AB	21 years
Sofia Heigis	F	44	ONCOPEPTIDES AB	4 years
Thoas Michael Fioretos	M	66	CANTARGIA AB	15 years
Eugen Steiner	M	70	BIOARCTIC AB	7 years
Göran Forsberg	M	61	CANTARGIA AB	10 years
Karolina Vilval	F	45	ONCOPEPTIDES AB Oncopeptides Incentive AB	3 years
Patricia Delaite	M	61	CANTARGIA AB	7 years
Flavia Borellini	M	65	CANTARGIA AB	4 years
Karin Leandersson	F	52	CANTARGIA AB	8 years
Bengt Håkan Englund	M	72	BIOARCTIC AB	4 years
Gunilla Christina Osswald	M	63	BIOARCTIC AB	11 years
Jan Mattsson	M	64	BIOARCTIC AB	7 years
Jennifer Jackson	M	71	ONCOPEPTIDES AB	6 years
Joachim Feldwisch	M	-	Affibody Medical AB Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.	-
Lennart Rolf Ivar Verner	M	77	BIOARCTIC AB	14 years
Martin Duvall	M	62	ONCOPEPTIDES AB Oncopeptides Incentive AB	2 years
Oskar Bosson	M	48	BIOARCTIC AB	4 years
Åke Mikael Smedeby	M	56	BIOARCTIC AB	6 years
Gunnar Magnus Modee Persson	M	64	CANTARGIA AB	8 years
Stig Anders Lindberg	M	52	Oncopeptides Incentive AB Affibody Medical AB Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.	-
Karin Nord	M	-	Affibody Medical AB Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.	26 years
Carl Erik Mathias Uhlén	M	70	Affibody Medical AB Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.	26 years
Charlotta Ljungqvist	M	63	BIOARCTIC AB	3 years
Damian Marron	M	62	CANTARGIA AB	3 years
Magnus Nilsson	M	68	CANTARGIA AB	3 years
Anna-Kaija Grönblad	F	56	BIOARCTIC AB	3 years
Camilla Soenderby	F	-	Affibody Medical AB Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.	-
Lotta Larsson	F	-	RAYSEARCH LABORATORIES AB	14 years
Gunilla Andersson	F	63	BIOARCTIC AB	5 years
David Liberg	M	55	CANTARGIA AB	9 years
Johanna Fälting	M	52	BIOARCTIC AB	12 years
Patrik Renblad	M	54	CANTARGIA AB	1 years
Lars Thorsson	M	63	CANTARGIA AB	9 years
Liselotte Larsson	M	61	CANTARGIA AB	10 years
Lars Jordeby	M	59	RAYSEARCH LABORATORIES AB	10 years
Alan Hulme	M	-	Oncopeptides Incentive AB	-
David Bejker	M	49	Affibody Medical AB Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.	6 years
Robert Forbes Burns	M	77	Affibody Medical AB Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.	-
Dominique Tersago	M	62	CANTARGIA AB	2 years
Tomas Odergren	M	65	BIOARCTIC AB	5 years
Peter Kemlin	M	50	RAYSEARCH LABORATORIES AB	12 years
Cecilia Marie Edström	F	58	BIOARCTIC AB	1 years
Jose F. Suarez	M	54	Affibody Medical AB Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.	-
Nedjad Losic	M	54	CANTARGIA AB	3 years
Christer Möller	M	65	BIOARCTIC AB	18 years
J. Kenneth Charles Knowles	M	77	Affibody Medical AB Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.	-

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Wenche Nelly A. Rolfsen Sandsborg	M	72	BIOARCTIC AB	7 years
Rolf Gulliksen	M	65	ONCOPEPTIDES AB	3 years
Peter Thysell	M	54	RAYSEARCH LABORATORIES AB	6 years
Victoria Sörving	F	38	RAYSEARCH LABORATORIES AB	-
Johan Georg Harmenberg	M	70	ONCOPEPTIDES AB	7 years
Klaas Bakker	M	42	ONCOPEPTIDES AB	-
Roger Belusa	M	-	CANTARGIA AB	-
Susanne Lagerlund	F	56	CANTARGIA AB	3 years
Peter Juul Madsen	M	-	CANTARGIA AB	2 years
Ignacio Garcia-Ribas	M	-	CANTARGIA AB	2 years
Karin Eklund Vanderpol	F	51	ONCOPEPTIDES AB	2 years
Linda Holmström	F	-	ONCOPEPTIDES AB	-
Corinne Savill	M	64	CANTARGIA AB	-
Christian Jacques	M	68	ONCOPEPTIDES AB	2 years
Elisabeth Augustsson	F	59	ONCOPEPTIDES AB	5 years
Bengt Jöndell	M	64	CANTARGIA AB	6 years
Annika Muskantor	F	58	ONCOPEPTIDES AB	2 years
Karin Birgitta Margareta Ståhl	F	53	ONCOPEPTIDES AB	2 years
Claus Asbjørn Andersson	M	56	CANTARGIA AB	8 years
Rein Piir	M	66	ONCOPEPTIDES AB	4 years
Han Jing Xie	M	54	ONCOPEPTIDES AB	2 years

Statistics

Country	Connections	% of total
Sweden	68	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections